Amarin Corporation (NASDAQ: AMRN) is a neuroscience company focused on the research, development and commercialization of novel drugs that address unmet patient needs. Amarin is committed to improving the lives of patients suffering from central nervous system and cardiovascular diseases.
Amarin continues to focus their efforts on employing a novel, proprietary platform based on knowledge of the chemical nature and highly vascular environment of the brain to develop pharmaceuticals in the area of neurology. The company’s unique technology of lipophilic drugs is predominately fat-soluble, which helps facilitate transportation across the blood-brain barrier. This is a crucial component since the majority of drugs that are currently available to treat neurological and psychiatric disorders have mechanisms of action targeting receptors of the brain or neurotransmitters located in the brain’s makeup.
The company has initiated a cardiovascular development program to capitalize on the known therapeutic benefits of unsaturated fatty acids in cardiovascular disease. Amarin plans to utilize their extensive know-how and vast experience in lipid science to develop a series of products targeting the vascular system, endothelial dysfunction and vascular re-modeling. Amarin intends on commencing a series of clinical trials with AMR 101 in cardiovascular disease. In addition, Amarin plans to begin an extensive investigation of new compounds from their already existing lipid science platform for the treatment of cardiovascular disease.
Their current neuroscience development pipeline is comprised of four key clinical development programs plus several pre-clinical opportunities. Clinical programs include AMR 101 for Huntington’s disease, EN 101 for Myasthenia gravis, an oral formulation of apomorphine for treating advanced Parkinson’s disease and patient’s who experience frequent “off” episodes. Additional treatments include a nasal formulation of lorazepam for treating emergency epilepsy seizures in the out-patient setting, and brain targeted delivery of levodopa for Parkinson’s disease which utilizes Amarin’s targeted transport lipid technology.
About QualityStocks:
QualityStocks’ Small Cap Stock Newsletter is a free service that collects data from hundreds of Small-Cap online Investment Newsletters into one free Daily Newsletter Report.
Sign up for “The QualityStocks Daily Newsletter” please visit www.QualityStocks.net
The Quality Stocks Daily Stock Report http://video.qualitystocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment